Successful engineering of a highly potent single-chain variable-fragment (scFv) bispecific antibody to target disialoganglioside (GD2) positive tumors
出版年份 2016 全文链接
标题
Successful engineering of a highly potent single-chain variable-fragment (scFv) bispecific antibody to target disialoganglioside (GD2) positive tumors
作者
关键词
-
出版物
OncoImmunology
Volume 5, Issue 6, Pages e1168557
出版商
Informa UK Limited
发表日期
2016-05-06
DOI
10.1080/2162402x.2016.1168557
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Alteration of Electrostatic Surface Potential Enhances Affinity and Tumor Killing Properties of Anti-ganglioside GD2 Monoclonal Antibody hu3F8
- (2015) Qi Zhao et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study
- (2015) Max S Topp et al. LANCET ONCOLOGY
- Alternative molecular formats and therapeutic applications for bispecific antibodies
- (2015) Christoph Spiess et al. MOLECULAR IMMUNOLOGY
- Engineering disulfide bonds within an antibody
- (2014) Yoshihisa Hagihara et al. BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS
- Structural design of disialoganglioside GD2 and CD3-bispecific antibodies to redirect T cells for tumor therapy
- (2014) Ming Cheng et al. INTERNATIONAL JOURNAL OF CANCER
- GD2-Targeted Immunotherapy and Radioimmunotherapy
- (2014) Konstantin Dobrenkov et al. SEMINARS IN ONCOLOGY
- Affinity improvement of a therapeutic antibody to methamphetamine and amphetamine through structure-based antibody engineering
- (2014) Shraddha Thakkar et al. Scientific Reports
- Retargeting T Cells to GD2 Pentasaccharide on Human Tumors Using Bispecific Humanized Antibody
- (2014) H. Xu et al. Cancer Immunology Research
- Vaccination for the prevention and treatment of breast cancer with special focus on Her-2/neu peptide vaccines
- (2013) Ursula Wiedermann et al. BREAST CANCER RESEARCH AND TREATMENT
- Engineering anti-GD2 monoclonal antibodies for cancer immunotherapy
- (2013) Mahiuddin Ahmed et al. FEBS LETTERS
- Murine Anti-GD2 Monoclonal Antibody 3F8 Combined With Granulocyte-Macrophage Colony-Stimulating Factor and 13-Cis-Retinoic Acid in High-Risk Patients With Stage 4 Neuroblastoma in First Remission
- (2012) Nai-Kong V. Cheung et al. JOURNAL OF CLINICAL ONCOLOGY
- Anti-CD3 × anti-GD2 bispecific antibody redirects T-cell cytolytic activity to neuroblastoma targets
- (2012) Maxim Yankelevich et al. PEDIATRIC BLOOD & CANCER
- Systemic administration of a bispecific antibody targeting EGFRvIII successfully treats intracerebral glioma
- (2012) B. D. Choi et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Humanizing murine IgG3 anti-GD2 antibody m3F8 substantially improves antibody-dependent cell-mediated cytotoxicity while retaining targeting in vivo
- (2012) Nai-Kong V. Cheung et al. OncoImmunology
- EpCAM/CD3-Bispecific T-cell Engaging Antibody MT110 Eliminates Primary Human Pancreatic Cancer Stem Cells
- (2011) M. Cioffi et al. CLINICAL CANCER RESEARCH
- Inhibitory signaling blocks activating receptor clustering and induces cytoskeletal retraction in natural killer cells
- (2011) Thushara P. Abeyweera et al. JOURNAL OF CELL BIOLOGY
- Redirected Lysis of Human Melanoma Cells by a MCSP/CD3-bispecific BiTE Antibody That Engages Patient-derived T Cells
- (2011) Hitoe Torisu-Itakura et al. JOURNAL OF IMMUNOTHERAPY
- Epitope distance to the target cell membrane and antigen size determine the potency of T cell-mediated lysis by BiTE antibodies specific for a large melanoma surface antigen
- (2010) Claudia Bluemel et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Anti-GD2 Antibody with GM-CSF, Interleukin-2, and Isotretinoin for Neuroblastoma
- (2010) Alice L. Yu et al. NEW ENGLAND JOURNAL OF MEDICINE
- Engineering an antibody with picomolar affinity to DOTA chelates of multiple radionuclides for pretargeted radioimmunotherapy and imaging
- (2010) Kelly Davis Orcutt et al. NUCLEAR MEDICINE AND BIOLOGY
- Stability engineering of scFvs for the development of bispecific and multivalent antibodies
- (2010) Brian R. Miller et al. PROTEIN ENGINEERING DESIGN & SELECTION
- The Prioritization of Cancer Antigens: A National Cancer Institute Pilot Project for the Acceleration of Translational Research
- (2009) M. A. Cheever et al. CLINICAL CANCER RESEARCH
- Tumor Regression in Cancer Patients by Very Low Doses of a T Cell-Engaging Antibody
- (2008) R. Bargou et al. SCIENCE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started